Through Scientific, Inc., a new Cambridge-based technology and AI company exits Stealth and launches a ground-breaking multi-Omics Analytics platform

CAMBRIDGE, MA., February 2, 2023 /PRNewswire/ — Via Scientific, Cambridge a technology and artificial intelligence-based company, is proud to announce the launch of Foundry, a multi-omics accelerator platform focused on significantly shortening the path to scientific breakthroughs.

Via Scientific, Inc.

Through Scientific, Inc., a new analytics company based in Cambridge, is launching an innovative Multi-Omics analytics platform.

The Foundry platform was originally developed at UMass Chan Medical School; Via Scientific has exclusive commercial rights to the Platform. They are the founders of the company Melissa J. MoorePhD Chief Scientist Emeritus at Moderna, Alper Kucukural, PhD Co-Director of the Bioinformatics Core at UMass Chan Medical School and CTO of Via Scientific, Manuel GarberPhD, co-director of the Bioinformatics Core at UMass Chan School of Medicine, Jim Crowleylocal tech and AI entrepreneur and Janet Koslofffounder of healthcare analytics company InCrowd, Inc.

Foundry automates the complex data and analytical work associated with multi-omics research. Featuring a powerful drag-and-drop pipeline and metadata building functionality that eliminates the need to write code, plus full process orchestration and adaptive analytics, Foundry is a force multiplier for biomedical researchers. The platform also ensures that all data and analytics are shareable, reusable and reproducible. This frees up time and resources for both researchers and bioinformaticians to concentrate on generating basic science insights and therapeutic breakthroughs.

“We are excited to introduce Foundry to the market,” said Melissa Moore. “As both an academic and CSO at Moderna, I saw firsthand the need for a powerful and adaptable tool like Foundry. Scientists are constantly challenged to maintain our ability to ask questions and imagine possibilities. Foundry transforms ‘process time’ into ‘science’ time, so research teams can focus on unlocking the underlying science that leads to new insights and discoveries.”

“Multiomics analysis is insanely difficult, and we’ve made it our mission to simplify this vital research area,” he added Jim Crowley, CEO of Via Scientific. “Scientists shouldn’t have to spend their time wrangling data, writing code, and coordinating development tasks just to get to the point where they can start asking their questions.” The foundry changes all that, as scientists will now spend their time where it’s meant to be – exploring experimental results, shaping insights and advancing understanding.”

Via Scientific is focused on supporting the analytical needs of biotech, pharmaceutical, research institutes and academic universities, as well as further developing the Foundry platform and expanding its AI capabilities.

About Via Scientific: Via Scientific, Inc., is a Cambridge, Massachusettsa bioinformatics and analytical technology company. The company was founded in 2022 and went public in February 2023 after a year in stealth mode. The company’s Foundry platform, available both in the cloud and as an on-premises solution, radically simplifies multiomics and enterprise-scale analytics. Via Scientific is growing rapidly and individuals with exceptional engineering, AI and bioinformatics skills can contact the company at [email protected] Learn more at

About the UMass School of Medicine Chan
UMass Chan Medical School, one of the five campuses of the University of Massachusetts system, includes TH Chan School in medicine; Morningside Graduate School of Biomedical Sciences; Tan Chingfen Graduate School of Nursing; Commonwealth Medicine, Community Services Consultancy; and MassBiologiks, the only non-profit FDA-licensed manufacturer of vaccines, biologics and viral vector gene therapies in United States. UMass Chan’s mission is to improve the health and well-being of our diverse communities everywhere Massachusetts and around the world by leading and innovating in education, research, health care delivery and public service. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education, perennially ranked in the top 10 percent of primary care medical schools by US News and World Report. UMass Chan attracts more than 300 million dollars annually in research funding, placing it among the top 50 medical schools in the nation. In 2021, the Medical School received a 175 million dollars donated by The Morningside Foundation and renamed UMass Chan Medical School.



View original media download content: and -launches innovative-multi-omics-analytics-platform-301737370.html

SOURCE Via Scientific, Inc.

Leave a Comment

Your email address will not be published. Required fields are marked *